Search 

Regulating Nitrosylation for Multi-Disease Therapies

SAJE Pharma’s S‑nitrosoglutathione reductase (GSNOR) inhibition technology regulates nitric oxide signal transduction pathways that are critical for multiple therapeutic benefits.  SAJE’s small molecule drugs regulate nitrosylation by inhibiting GSNOR.  Many biologists consider that “Nitrosylation is the new phosphorylation”, meaning that nitrosylation regulates cell pathways as directly as does phosphorylation.  The big advantage for SAJE is that there is only one human GSNOR to inhibit as compared to 100’s of phosphorylation targets, making it a much more “druggable” target with less possibility for off-target toxicity.  SAJE and its collaborators have discovered that GSNOR inhibition reduces: inflammation, oxidant damage, fibrosis, mucus accumulation, and bronchoconstriction.  Such multiple therapeutic efficacies by inhibiting only one enzyme with small molecules is unprecedented in pharmacology.  SAJE is focused on idiopathic pulmonary fibrosis and asthma as its first clinical applications, although there is animal data for efficacy in other diseases including cardiovascular, metabolic, inflammatory, liver, kidney, and other respiratory.  One GSNOR inhibitor has shown Clinical Proof of Concept for GSNOR as a target in a Phase IIa trial in asthma.

SAJE Pharma’s executive team consists of experienced drug development scientists and serial entrepreneurs whose backgrounds include FDA, large pharma, start-up companies, and the CRO industry.

SAJE has licensed one patent app that is nearing issuance in the EU and the US.  It protects SPL-334, SAJE’s lead molecule, and other related molecules.  In addition, SAJE is close to filing 3 more patent apps on its novel compositions that inhibit GSNOR.  A clear advantage for our drugs compared to many novel therapies  is the cost of goods.  Our drugs will cost pennies per dose.

SAJE would like to raise $15 MM to take SPL-334 through a Phase IIa trial in IPF.  The drug is ready for IND-enabling studies.  The company’s exit strategy is to out-license each of its drugs and their accompanying data set, one at a time, for different diseases in different categories.

Sanus Asia is a Singapore based advisory firm providing investment and transaction-related services across Asia with a focus on Healthcare and Life Sciences.

We work with investors and high potential companies to assist growth/development across Asia through capital raising and strategic/operational support.

We seek to identify high potential US/European Medtech and Digital Health companies with near-term commercialisation potential in Asia.

Will also consider earlier stage investments as a principal Angel investor if there is a strong Asian angle to the technology/business model.

Sathguru Management Consultants is a niche emerging markets focused strategy and innovation advisory firm.  Founded in 1985 in India, Sathguru’s expertise includes South Asia focused corporate strategy, M&A and innovation advisory encompassing international innovation access, advancement and commercialization.  Sathguru has a team of around 150 professionals across service offerings and has offices in India and USA. 

SENS Research Foundation is based in Mountain View, CA. The foundation provides grants for research into rejuvenation biotechnologies that prevent or reverse age-related tissue damage. Historically grants have ranged from $40,000 to $200,000 although this range may change in the future. Grants are available to researchers worldwide. SENS requests that grants not be used to cover overhead/facilities costs. At present, 15 projects are being supported.